Merus NV
MRUS68.220USD
-0.730-1.06%
Cierre 09/19, 16:00（ET）Cotizaciones retrasadas 15 min
5.16BCap. mercado
PérdidaP/E TTM
Más Datos de Merus NV Compañía
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.
Información de la empresa
Símbolo de cotizaciónMRUS
Nombre de la empresaMerus NV
Fecha de salida a bolsaMay 19, 2016
Director ejecutivoDr. Sven Ante (Bill) Lundberg, M.D.
Número de empleados260
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 19
DirecciónYalelaan 62
CiudadUTRECHT
Bolsa de valoresNASDAQ Global Market Consolidated
PaísNetherlands
Código postal3584 CM
Teléfono310302538800
Sitio Webhttps://merus.nl/
Símbolo de cotizaciónMRUS
Fecha de salida a bolsaMay 19, 2016
Director ejecutivoDr. Sven Ante (Bill) Lundberg, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
198.74K
+55.46%
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Peter B. Silverman, J.D.
Mr. Peter B. Silverman, J.D.
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
--
--
Ms. Sherri Spear
Ms. Sherri Spear
Investor Relations and Corporate Communications
Investor Relations and Corporate Communications
--
--
Mr. Jason Haddock
Mr. Jason Haddock
Director
Director
--
--
Dr. Fabian Zohren, M.D., Ph.D
Dr. Fabian Zohren, M.D., Ph.D
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Leonard (Len) Kanavy
Mr. Leonard (Len) Kanavy
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Gregory D. (Greg) Perry
Mr. Gregory D. (Greg) Perry
Chief Financial Officer
Chief Financial Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
198.74K
+55.46%
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Peter B. Silverman, J.D.
Mr. Peter B. Silverman, J.D.
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
--
--
Ms. Sherri Spear
Ms. Sherri Spear
Investor Relations and Corporate Communications
Investor Relations and Corporate Communications
--
--
Mr. Jason Haddock
Mr. Jason Haddock
Director
Director
--
--
Dr. Fabian Zohren, M.D., Ph.D
Dr. Fabian Zohren, M.D., Ph.D
Chief Medical Officer
Chief Medical Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 15 de ago
Actualizado: vie., 15 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
8.22%
Paradigm BioCapital Advisors LP
5.66%
RTW Investments L.P.
5.29%
Wellington Management Company, LLP
4.93%
Commodore Capital LP
4.66%
Otro
71.24%
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
8.22%
Paradigm BioCapital Advisors LP
5.66%
RTW Investments L.P.
5.29%
Wellington Management Company, LLP
4.93%
Commodore Capital LP
4.66%
Otro
71.24%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
37.28%
Hedge Fund
34.60%
Investment Advisor
26.56%
Corporation
1.93%
Venture Capital
1.78%
Research Firm
1.13%
Private Equity
0.94%
Individual Investor
0.37%
Pension Fund
0.35%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
411
75.46M
99.77%
-10.50M
2025Q1
420
74.82M
101.12%
-10.15M
2024Q4
398
74.69M
108.18%
-7.45M
2024Q3
373
72.99M
107.03%
-6.71M
2024Q2
355
69.91M
103.77%
+7.77M
2024Q1
315
57.35M
97.63%
-5.32M
2023Q4
282
57.36M
99.41%
-5.55M
2023Q3
268
57.60M
100.50%
+2.76M
2023Q2
260
49.90M
100.83%
+114.35K
2023Q1
250
43.88M
95.34%
-4.11M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Fidelity Management & Research Company LLC
5.62M
7.55%
-39.01K
-0.69%
Mar 31, 2025
Paradigm BioCapital Advisors LP
3.55M
4.77%
+184.36K
+5.47%
Apr 03, 2025
RTW Investments L.P.
4.17M
5.6%
--
--
Mar 31, 2025
Wellington Management Company, LLP
4.72M
6.34%
+1.22M
+34.90%
Mar 31, 2025
Commodore Capital LP
4.47M
6.01%
+598.66K
+15.45%
Mar 31, 2025
Deerfield Management Company, L.P.
3.17M
4.26%
+201.14K
+6.77%
Mar 31, 2025
Avoro Capital Advisors LLC
3.00M
4.03%
+875.00K
+41.18%
Mar 31, 2025
T. Rowe Price Associates, Inc.
1.10M
1.47%
-21.08K
-1.89%
Mar 31, 2025
Holocene Advisors, LP
1.87M
2.52%
-6.39K
-0.34%
Mar 31, 2025
Westfield Capital Management Company, L.P.
1.50M
2.02%
+508.06K
+51.16%
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
